Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer

Clinical Trial ID NCT00203502

Rank	Title	Journal	Year	PubWeight™‹?›
1	Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.	Am J Clin Oncol	2015	0.94
2	High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.	Am J Clin Oncol	2016	0.92
3	Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.	PLoS One	2017	0.83